{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:10:34Z","timestamp":1781079034109,"version":"3.54.1"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shanghai Municipal Health Commission, China","award":["2024ZZ2038"],"award-info":[{"award-number":["2024ZZ2038"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effectiveness of administering additional intravitreal topotecan injections (plus two) in reducing the recurrence rate in patients with advanced retinoblastoma (RB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This retrospective, non-comparative and interventional study encompassed 26 eyes of 25 patients with RB, treated between January 2019 and April 2024. All eyes in this series had received previous intravenous chemotherapy and\/or intra-arterial chemotherapy. Patients received intravitreal topotecan (30\u2009\u00b5g\/0.1\u2009mL) and\/or intravitreal melphalan (20\u201330\u2009\u00b5g\/0.1\u2009mL) injections every 3\u20134 weeks until vitreous seeds regression was achieved. Subsequently, two additional injections of topotecan (30\u2009\u00b5g\/0.1\u2009mL) were administered after complete regression to consolidate subclinical residuals. The control of vitreous seeds, ocular toxicity assessment and clinical characteristics was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of the patients was 26 months, with 57.7% belonging to group D and 42.3% to group E of RB classification. A total of 111 injections were administered in 26 eyes, with a median of 4 injections per eye. Complete vitreous seeds regression was achieved in 100% of eyes, and eye salvage was successful in 24 of 26 eyes (92.3%). There were no recurrences of vitreous seeds. Enucleation was performed in two eyes: one due to phthisis bulbi and one due to optic nerve tumour recurrence. No cases of systemic metastasis or death were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Administering additional intravitreal topotecan injections (plus two) following the complete regression of vitreous seeds may contribute to reducing the recurrence rate in patients with RB. This approach enhances the long-term efficacy of intravitreal injections, thereby contributing to higher eye salvage rates.<\/jats:p>\n                    <jats:p>However, the retrospective, non-randomised design and small sample size remain limitations. Multicentre prospective studies are warranted to validate these findings and refine treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002379","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T01:05:11Z","timestamp":1762131911000},"page":"e002379","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study"],"prefix":"10.1136","volume":"10","author":[{"given":"Xintong","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Eye Ear Nose and Throat Hospital of Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia of the State Health Ministry, and Key Laboratory of Visual Impairment and Restoration of Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuqing","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eye Ear Nose and Throat Hospital of Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia of the State Health Ministry, and Key Laboratory of Visual Impairment and Restoration of Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eye Ear Nose and Throat Hospital of Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia of the State Health Ministry, and Key Laboratory of Visual Impairment and Restoration of Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eye Ear Nose and Throat Hospital of Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia of the State Health Ministry, and Key Laboratory of Visual Impairment and Restoration of Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Eye Ear Nose and Throat Hospital of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eye Ear Nose and Throat Hospital of Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia of the State Health Ministry, and Key Laboratory of Visual Impairment and Restoration of Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-0217","authenticated-orcid":false,"given":"Kang","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Eye Ear Nose and Throat Hospital of Fudan University, Shanghai, China"},{"name":"Key Laboratory of Myopia of the State Health Ministry, and Key Laboratory of Visual Impairment and Restoration of Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,2]]},"reference":[{"key":"2026010721213141000_10.1.e002379.1","doi-asserted-by":"publisher","DOI":"10.3109\/13816810.2014.973045"},{"key":"2026010721213141000_10.1.e002379.2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.ophtha.2017.04.015","article-title":"Vitreous Seeds in Retinoblastoma: Clinicopathologic Classification and Correlation","volume":"124","author":"Amram","year":"2017","journal-title":"Ophthalmology"},{"key":"2026010721213141000_10.1.e002379.3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10384-020-00743-2","article-title":"Comparison of intravitreal melphalan with and without topotecan in the management of vitreous disease in retinoblastoma","volume":"64","author":"Kiratli","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"2026010721213141000_10.1.e002379.4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ophtha.2013.09.011","article-title":"Management and outcome of retinoblastoma with vitreous seeds","volume":"121","author":"Manjandavida","year":"2014","journal-title":"Ophthalmology"},{"key":"2026010721213141000_10.1.e002379.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01348-X"},{"key":"2026010721213141000_10.1.e002379.6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaophthalmol.2013.7666","article-title":"Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results","volume":"132","author":"Shields","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2026010721213141000_10.1.e002379.7","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-300498"},{"key":"2026010721213141000_10.1.e002379.8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312037"},{"key":"2026010721213141000_10.1.e002379.9","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-318892"},{"key":"2026010721213141000_10.1.e002379.10","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-310641"},{"key":"2026010721213141000_10.1.e002379.11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ophtha.2024.04.022","article-title":"Intravitreal Topotecan for Vitreous Seeds in Retinoblastoma: A Long-term Review of 91 Eyes","volume":"131","author":"Sen","year":"2024","journal-title":"Ophthalmology"},{"key":"2026010721213141000_10.1.e002379.12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3928\/01913913-20200417-01","article-title":"Risk Factors for Tumor Recurrence Following Primary Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma in 869 Eyes of 551 Patients","volume":"57","author":"Dalvin","year":"2020","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2026010721213141000_10.1.e002379.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000004283","article-title":"HIGH-DOSE INTRAVITREAL TOPOTECAN FOR RECURRENT RETINOBLASTOMA, SUBRETINAL SEEDS, AND VITREOUS SEEDS","volume":"45","author":"Shields","year":"2025","journal-title":"Retina"},{"key":"2026010721213141000_10.1.e002379.14","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.150"},{"key":"2026010721213141000_10.1.e002379.15","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","article-title":"Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications","volume":"96(8)","author":"Munier","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"2026010721213141000_10.1.e002379.16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23002"},{"key":"2026010721213141000_10.1.e002379.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-019-1059-4","article-title":"Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients","volume":"19","author":"Xue","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"2026010721213141000_10.1.e002379.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146582","article-title":"Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma","volume":"11","author":"Abramson","year":"2016","journal-title":"PLoS One"},{"key":"2026010721213141000_10.1.e002379.19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/archopht.120.4.460","article-title":"Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma","volume":"120","author":"Shields","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"2026010721213141000_10.1.e002379.20","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318529"},{"key":"2026010721213141000_10.1.e002379.21","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318295f783"},{"key":"2026010721213141000_10.1.e002379.22","doi-asserted-by":"crossref","unstructured":"Berry JL , Shah S , Bechtold M , et al . Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer 2017;64. doi:10.1002\/pbc.26696","DOI":"10.1002\/pbc.26696"},{"key":"2026010721213141000_10.1.e002379.23","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/IAE.0000000000000903","article-title":"INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture","volume":"36","author":"Shields","year":"2015","journal-title":"Retina (Philadelphia, Pa)"},{"key":"2026010721213141000_10.1.e002379.24","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.3928\/01913913-20230110-01","article-title":"Intravitreal Topotecan 90 \u00b5g for Recurrent Solid Retinoblastoma Tumors Is Effective and Not Toxic","volume":"60","author":"Abramson","year":"2023","journal-title":"J Pediatr Ophthalmol Strabismus"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:22:25Z","timestamp":1767849745000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,2]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjophth-2025-002379"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002379","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}